POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) — BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products,…
POMPANO BEACH, Fla., March 31, 2026 — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced…
POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
POMPANO BEACH, FL, March 24, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products,…
POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) — BioStem Technologies (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound…
POMPANO BEACH, Fla., March 11, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative…
POMPANO BEACH, Fla., February 3, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products…
POMPANO BEACH, FL, January 21, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental derived products for advanced wound care, today announced the closing of a definitive asset purchase agreement with BioTissue Holdings Inc, a pioneer and leader…
Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing,…
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains…
